(NASDAQ: RGEN) Repligen's forecast annual revenue growth rate of 10.11% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 7.66%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.04%.
Repligen's revenue in 2024 is $607,450,000.On average, 7 Wall Street analysts forecast RGEN's revenue for 2024 to be $35,620,267,790, with the lowest RGEN revenue forecast at $35,340,385,437, and the highest RGEN revenue forecast at $35,872,323,948. On average, 7 Wall Street analysts forecast RGEN's revenue for 2025 to be $40,874,333,979, with the lowest RGEN revenue forecast at $40,104,364,160, and the highest RGEN revenue forecast at $41,610,778,262.
In 2026, RGEN is forecast to generate $47,142,771,147 in revenue, with the lowest revenue forecast at $46,120,242,287 and the highest revenue forecast at $48,892,524,768.